NCT03269422View on ClinicalTrials.gov

Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

August 28, 2026

Study Completion Date

August 28, 2026

Conditions
Prostate Cancer
Interventions
RADIATION

MR-based image-guided, intensity-modulated radiotherapy

Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau (Consent and follow up), Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge (Consent only and follow up), Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER